<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03596970</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001HDE53</org_study_id>
    <nct_id>NCT03596970</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.</brief_title>
  <acronym>Prometheus</acronym>
  <official_title>A 24-month Multi-center, Open-label, Randomized, Controlled Study to Evaluate the Evolution of Renal Function in Maintenance Liver Transplant Recipients Receiving Either RAD001 (Everolimus) Plus Reduced TAC or RAD001 (Everolimus) Plus Mycophenolate Mofetil (MMF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 24-month multi-center, open-label, randomized, controlled study to evaluate the evolution
      of renal function in maintenance liver transplant recipients receiving everolimus plus
      reduced TAC or everolimus plus mycophenolate mofetil (MMF)
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal Function</measure>
    <time_frame>Randomization to Month 6</time_frame>
    <description>The primary variable will be the mean change in renal function assessed by eGFR from randomization to Month 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy (tBPAR, graft loss, death, loss to follow-up)</measure>
    <time_frame>To Month 6</time_frame>
    <description>Composite efficacy failure of tBPAR, graft loss, death or loss to follow-up and each of its components at month 6 will be analysed per event rate estimates, Kaplan-Meier and regression models. The time to the first occurrence of the event will be calculated from the randomization date.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>at 24 months (end of study)</time_frame>
    <description>Routine safety will be assessed via AE reporting, vital signs, and laboratory data.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Everolimus with MMF (TAC-withdrawal)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus (RAD001) with MMF and Steroids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus with reduced TAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Everolimus (RAD001) with reduced TAC and Steroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAC withdrawal</intervention_name>
    <description>Everolimus (RAD001) with MMF and Steroids</description>
    <arm_group_label>Everolimus with MMF (TAC-withdrawal)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus with reduced TAC</intervention_name>
    <description>Active comparator arm: Everolimus (RAD001) with reduced TAC and Steroids</description>
    <arm_group_label>Everolimus with reduced TAC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients willing and capable of providing written informed consent for study
             participation.

          -  Adults 18 to 70 years of age.

          -  Liver allograft from a deceased or living donor.

          -  Treated with a CNI containing immunosuppressive regimen.

          -  Liver transplant 6 to 24 months prior to screening.

          -  Estimated kidney function between chronic kidney disease (CKD) IIIb/ 30 mL/min &lt; eGFR
             &lt; CKD II/60 mL/min with deteriorating renal function.

          -  Acceptable graft function (according to liver enzymes (AST / ALT) and total
             bilirubin).

        Exclusion Criteria:

          -  Multiple solid organ transplant recipients

          -  Active chronic inflammatory bowel disease and recurrent autoimmune hepatitis

          -  Malignant diseases other than neoplasms of the skin.

          -  Patient on other investigational drug or presence of any hypersensitivity to the
             interventional drug.

          -  Pregnant or nursing (lactating) women.

          -  Women of child-bearing potential (physiologically capable of becoming pregnant, unless
             they are using effective methods of contraception).

          -  Anemia, thrombocytopenia, leucopenia, uncontrolled hyperlipidemia or proteinuria

          -  HIV positivity

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 25, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>July 13, 2018</last_update_submitted>
  <last_update_submitted_qc>July 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open-label</keyword>
  <keyword>randomized</keyword>
  <keyword>calcineurin-inhibitor</keyword>
  <keyword>CNI</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>MMF</keyword>
  <keyword>maintenance liver transplant</keyword>
  <keyword>RAD001H</keyword>
  <keyword>CRAD001H</keyword>
  <keyword>liver transplant</keyword>
  <keyword>transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

